Gefitinib plus docetaxel in non-small-cell lung cancer

Lancet. 2009 Feb 14;373(9663):541; author reply 542. doi: 10.1016/S0140-6736(09)60192-6.
No abstract available

Publication types

  • Letter
  • Kommentar

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Docetaxel
  • ErbB Receptors / drug effects
  • ErbB Receptors / genetics
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Protein Kinase Inhibitors / therapeutic use*
  • Quinazolines / administration & dosage
  • Quinazolines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Taxoids / administration & dosage
  • Taxoids / therapeutic use*

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Protein Kinase Inhibitors
  • Quinazolines
  • Taxoids
  • Docetaxel
  • EGFR protein, human
  • ErbB Receptors
  • Gefitinib